BRIEF-Kymera Plans To Initiate A KT-621 Phase 1B Trial In Atopic Dermatitis Patients In 2Q25 With Data In 4Q25

Reuters
14 Jan

Jan 14 (Reuters) - Kymera Therapeutics Inc :

* KYMERA: PLANS TO INITIATE A KT-621 PHASE 1B TRIAL IN ATOPIC DERMATITIS PATIENTS IN 2Q25 WITH DATA IN 4Q25

* KYMERA: TO INITIATE PARALLEL PHASE 2B TRIALS IN AD AND ASTHMA IN LATE 2025 AND EARLY 2026, RESPECTIVELY

* KYMERA: WELL-CAPITALIZED WITH $850 MILLION IN CASH AND RUNWAY INTO MID-2027

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10